{
    "id": "correct_subsidiary_00058_2",
    "rank": 14,
    "data": {
        "url": "https://www.bioworld.com/articles/358246-through-long-recovery-elan-shifts-from-pharma-to-biotech",
        "read_more_link": "",
        "language": "en",
        "title": "Through Long Recovery, Elan Shifts From Pharma To Biotech",
        "top_image": "https://www.bioworld.com/icons/favicon-32x32.png",
        "meta_img": "https://www.bioworld.com/icons/favicon-32x32.png",
        "images": [
            "https://www.bioworld.com/images/Cortellis_Flagship_Logo.png",
            "https://www.bioworld.com/images/Cortellis_Flagship_Logo_TM_RGB_Color.png",
            "https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-illustration1.png?height=355&t=1613684293&width=640",
            "https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Stock-merger-illustration.png?height=355&t=1620238968&width=640",
            "https://www.bioworld.com/ext/resources/Ads/2024/bioworld-advertising-reach.jpg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            "Biologics",
            "Biopharmaceutical",
            "Biotechnology",
            "Drug",
            "EMA",
            "FDA",
            "Health",
            "Medical",
            "Medical device",
            "Medical technology",
            "Pharmaceutical"
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology sectors. In-depth coverage of innovation, business, financing, regulation, science, product development, clinical trials and more",
        "meta_lang": "en",
        "meta_favicon": "/icons/apple-touch-icon.png",
        "meta_site_name": "",
        "canonical_link": "https://www.bioworld.com/articles/358246-through-long-recovery-elan-shifts-from-pharma-to-biotech",
        "text": "Today's news in brief\n\nBioWorld briefs for July 22, 2024.\n\nToday's news in brief\n\nBioWorld MedTech briefs for July 22, 2024.\n\nDaiichi Sankyo reports orexin OX2 receptor agonists for narcolepsy\n\nDaiichi Sankyo Co. Ltd. has prepared and tested new 2-azabicyclo[3.1.1]heptane compounds acting as orexin OX2 receptor agonists with potential for the treatment...\n\nOrum scores potential $945M deal with Vertex for novel DACs\n\nOrum Therapeutics Inc. struck a potential $945 million (â‚©1.3 trillion) deal with Vertex Pharmaceuticals Inc. to discover novel degrader antibody conjugates (DAC)..."
    }
}